FIGURE 2.
FXIIa‐mediated kallikrein activity inhibition in volunteers receiving i.v. (a) and s.c. (b) garadacimab at a range of doses (PD analysis set). FXII, Factor XII; PD, pharmacodynamic
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.